The central cholinergic system profile of olanzapine compared with placebo in Alzheimer's disease

J. S. Kennedy, A. Zagar, F. Bymaster, G. Nomikos, P. T. Trzepacz, J. A. Gilmore, M. D. Rotelli, Alan Breier, G. Tollefson

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Objective: The objective of this analysis was to compare the treatment-emergent central anticholinergic-like adverse events experienced during treatment with olanzapine versus placebo in patients with psychosis and/or agitation due to Alzheimer's disease (AD). In addition, changes in cognition were assessed in a subgroup of patients with mild to moderate cognitive impairment. Methods: Double-blind data were compared for placebo and three fixed olanzapine dosages (5 mg/day, 10 mg/day, and 15 mg/day) in 206 nursing home-residing patients with AD for five a priori selected central nervous system anticholinergic-like adverse events: confusion, delirium, delusions, hallucinations, abnormal thinking. Mean change from baseline to endpoint on the Alzheimer's Disease Assessment Scale - Cognitive (ADAS-Cog) was measured for a subgroup of 43 patients who had mild to moderate cognitive impairment at baseline. Results: There were no significant differences in central anticholinergic-like adverse events at any olanzapine dose compared to placebo. Additionally, in the 43-patient subgroup, there were no significant differences in mean change in ADAS-Cog scores between placebo and the three olanzapine dose subgroups. Conclusion: Olanzapine did not differ significantly from placebo for any of the five central nervous system anticholinergic events nor on the ADAS-Cog. Olanzapine's initially reported potent in vitro muscarinic receptor affinity is not consistent with this clinical study of central nervous system anticholinergic-like adverse events in patients with AD.

Original languageEnglish (US)
JournalInternational Journal of Geriatric Psychiatry
Volume16
Issue numberSUPPL. 1
StatePublished - 2001

Fingerprint

olanzapine
Cholinergic Agents
Cholinergic Antagonists
Alzheimer Disease
Placebos
Central Nervous System
Confusion
Delusions
Delirium
Hallucinations
Muscarinic Receptors
Nursing Homes
Double-Blind Method
Psychotic Disorders
Cognition

Keywords

  • Alzheimer's disease
  • Olanzapine

ASJC Scopus subject areas

  • Geriatrics and Gerontology
  • Psychiatry and Mental health

Cite this

Kennedy, J. S., Zagar, A., Bymaster, F., Nomikos, G., Trzepacz, P. T., Gilmore, J. A., ... Tollefson, G. (2001). The central cholinergic system profile of olanzapine compared with placebo in Alzheimer's disease. International Journal of Geriatric Psychiatry, 16(SUPPL. 1).

The central cholinergic system profile of olanzapine compared with placebo in Alzheimer's disease. / Kennedy, J. S.; Zagar, A.; Bymaster, F.; Nomikos, G.; Trzepacz, P. T.; Gilmore, J. A.; Rotelli, M. D.; Breier, Alan; Tollefson, G.

In: International Journal of Geriatric Psychiatry, Vol. 16, No. SUPPL. 1, 2001.

Research output: Contribution to journalArticle

Kennedy, JS, Zagar, A, Bymaster, F, Nomikos, G, Trzepacz, PT, Gilmore, JA, Rotelli, MD, Breier, A & Tollefson, G 2001, 'The central cholinergic system profile of olanzapine compared with placebo in Alzheimer's disease', International Journal of Geriatric Psychiatry, vol. 16, no. SUPPL. 1.
Kennedy JS, Zagar A, Bymaster F, Nomikos G, Trzepacz PT, Gilmore JA et al. The central cholinergic system profile of olanzapine compared with placebo in Alzheimer's disease. International Journal of Geriatric Psychiatry. 2001;16(SUPPL. 1).
Kennedy, J. S. ; Zagar, A. ; Bymaster, F. ; Nomikos, G. ; Trzepacz, P. T. ; Gilmore, J. A. ; Rotelli, M. D. ; Breier, Alan ; Tollefson, G. / The central cholinergic system profile of olanzapine compared with placebo in Alzheimer's disease. In: International Journal of Geriatric Psychiatry. 2001 ; Vol. 16, No. SUPPL. 1.
@article{51070253aee4438ea5de73b365194bb4,
title = "The central cholinergic system profile of olanzapine compared with placebo in Alzheimer's disease",
abstract = "Objective: The objective of this analysis was to compare the treatment-emergent central anticholinergic-like adverse events experienced during treatment with olanzapine versus placebo in patients with psychosis and/or agitation due to Alzheimer's disease (AD). In addition, changes in cognition were assessed in a subgroup of patients with mild to moderate cognitive impairment. Methods: Double-blind data were compared for placebo and three fixed olanzapine dosages (5 mg/day, 10 mg/day, and 15 mg/day) in 206 nursing home-residing patients with AD for five a priori selected central nervous system anticholinergic-like adverse events: confusion, delirium, delusions, hallucinations, abnormal thinking. Mean change from baseline to endpoint on the Alzheimer's Disease Assessment Scale - Cognitive (ADAS-Cog) was measured for a subgroup of 43 patients who had mild to moderate cognitive impairment at baseline. Results: There were no significant differences in central anticholinergic-like adverse events at any olanzapine dose compared to placebo. Additionally, in the 43-patient subgroup, there were no significant differences in mean change in ADAS-Cog scores between placebo and the three olanzapine dose subgroups. Conclusion: Olanzapine did not differ significantly from placebo for any of the five central nervous system anticholinergic events nor on the ADAS-Cog. Olanzapine's initially reported potent in vitro muscarinic receptor affinity is not consistent with this clinical study of central nervous system anticholinergic-like adverse events in patients with AD.",
keywords = "Alzheimer's disease, Olanzapine",
author = "Kennedy, {J. S.} and A. Zagar and F. Bymaster and G. Nomikos and Trzepacz, {P. T.} and Gilmore, {J. A.} and Rotelli, {M. D.} and Alan Breier and G. Tollefson",
year = "2001",
language = "English (US)",
volume = "16",
journal = "International Journal of Geriatric Psychiatry",
issn = "0885-6230",
publisher = "John Wiley and Sons Ltd",
number = "SUPPL. 1",

}

TY - JOUR

T1 - The central cholinergic system profile of olanzapine compared with placebo in Alzheimer's disease

AU - Kennedy, J. S.

AU - Zagar, A.

AU - Bymaster, F.

AU - Nomikos, G.

AU - Trzepacz, P. T.

AU - Gilmore, J. A.

AU - Rotelli, M. D.

AU - Breier, Alan

AU - Tollefson, G.

PY - 2001

Y1 - 2001

N2 - Objective: The objective of this analysis was to compare the treatment-emergent central anticholinergic-like adverse events experienced during treatment with olanzapine versus placebo in patients with psychosis and/or agitation due to Alzheimer's disease (AD). In addition, changes in cognition were assessed in a subgroup of patients with mild to moderate cognitive impairment. Methods: Double-blind data were compared for placebo and three fixed olanzapine dosages (5 mg/day, 10 mg/day, and 15 mg/day) in 206 nursing home-residing patients with AD for five a priori selected central nervous system anticholinergic-like adverse events: confusion, delirium, delusions, hallucinations, abnormal thinking. Mean change from baseline to endpoint on the Alzheimer's Disease Assessment Scale - Cognitive (ADAS-Cog) was measured for a subgroup of 43 patients who had mild to moderate cognitive impairment at baseline. Results: There were no significant differences in central anticholinergic-like adverse events at any olanzapine dose compared to placebo. Additionally, in the 43-patient subgroup, there were no significant differences in mean change in ADAS-Cog scores between placebo and the three olanzapine dose subgroups. Conclusion: Olanzapine did not differ significantly from placebo for any of the five central nervous system anticholinergic events nor on the ADAS-Cog. Olanzapine's initially reported potent in vitro muscarinic receptor affinity is not consistent with this clinical study of central nervous system anticholinergic-like adverse events in patients with AD.

AB - Objective: The objective of this analysis was to compare the treatment-emergent central anticholinergic-like adverse events experienced during treatment with olanzapine versus placebo in patients with psychosis and/or agitation due to Alzheimer's disease (AD). In addition, changes in cognition were assessed in a subgroup of patients with mild to moderate cognitive impairment. Methods: Double-blind data were compared for placebo and three fixed olanzapine dosages (5 mg/day, 10 mg/day, and 15 mg/day) in 206 nursing home-residing patients with AD for five a priori selected central nervous system anticholinergic-like adverse events: confusion, delirium, delusions, hallucinations, abnormal thinking. Mean change from baseline to endpoint on the Alzheimer's Disease Assessment Scale - Cognitive (ADAS-Cog) was measured for a subgroup of 43 patients who had mild to moderate cognitive impairment at baseline. Results: There were no significant differences in central anticholinergic-like adverse events at any olanzapine dose compared to placebo. Additionally, in the 43-patient subgroup, there were no significant differences in mean change in ADAS-Cog scores between placebo and the three olanzapine dose subgroups. Conclusion: Olanzapine did not differ significantly from placebo for any of the five central nervous system anticholinergic events nor on the ADAS-Cog. Olanzapine's initially reported potent in vitro muscarinic receptor affinity is not consistent with this clinical study of central nervous system anticholinergic-like adverse events in patients with AD.

KW - Alzheimer's disease

KW - Olanzapine

UR - http://www.scopus.com/inward/record.url?scp=0012836543&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0012836543&partnerID=8YFLogxK

M3 - Article

VL - 16

JO - International Journal of Geriatric Psychiatry

JF - International Journal of Geriatric Psychiatry

SN - 0885-6230

IS - SUPPL. 1

ER -